Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jhep.2017.09.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections.
Diagnostics (Basel)
September 2023
Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Al-Baha University, Al-Baha 65522, Saudi Arabia.
Hepatitis C virus (HCV) is a hepatotropic virus that affects millions of human lives worldwide. Direct-acting antiviral (DAA) regimens are the most effective HCV treatment option. However, amino acid substitution-dependent resistance to DAAs has been a major challenge.
View Article and Find Full Text PDFMolecular characterization of patients with chronic hepatitis C virus infection in Jordan: implications on response to direct-acting antiviral therapy.
Int J Infect Dis
October 2023
Servicio de Microbiología, Hospital Universitario San Cecilio, Granada, Spain; Instituto de Investigación Biosanitaria Ibs.Granada, Granada, Spain; Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), ISCIII, 28046, Madrid, Spain.
Objectives: To investigate the molecular characteristics of Hepatitis C Virus (HCV) detected in patients with chronic HCV infection in Jordan.
Methods: The study included 48 Jordanian treatment-naïve patients with active chronic HCV recruited from seven governorates. HCV genotype and the resistance-associated substitutions (RAS) profile were investigated by next-generation sequencing of the NS5B, NS5A, and NS3 regions of HCV.
Pre-existing, treatment-specific resistance-associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct-acting antivirals.
APMIS
August 2023
Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark.
The introduction of direct-acting antiviral (DAA) treatment of hepatitis C virus (HCV) infected patients has greatly increased treatment success rates. However, viral response kinetics to DAA treatment may depend on pre-existing resistance-associated substitutions (RASs) in HCV. The aim of this study was to describe how pre-existing RASs affect DAA treatment-induced reduction in HCV RNA titers in HCV genotypes 1- and 3-infected individuals.
View Article and Find Full Text PDFHepatitis C Virus Genotype 5 Variability in Treatment-Naïve Patients in South Africa.
Intervirology
December 2023
HIV and Hepatitis Research Unit, Department of Virology, Sefako Makgatho Health Sciences University, Pretoria, South Africa.
Introduction: Hepatitis C virus (HCV) genotype 5 was originally identified in South Africa, where it represents 35-60% of all HCV infections. There are limited data on resistance-associated variants (RAVs) in South Africa. Thus, we investigated variability within the NS3/NS4A, NS5A, and NS5B genes of treatment-naïve individuals with HCV genotype 5 infection at the Dr.
View Article and Find Full Text PDFHuman pegivirus viremia in HCV/HIV co-infected patients: Direct acting antivirals exert anti-pegivirus effects.
J Clin Virol
May 2023
Department of Medicine, University of Alberta, Edmonton, AB, Canada. Electronic address:
Article Synopsis
- Human pegivirus (HPgV) is an RNA virus linked to hepatitis C and HIV, associated with potential cancer and neurological issues, but lacks established treatments.
- A study assessing HPgV prevalence in 100 HCV/HIV co-infected patients showed 26% had detectable HPgV, particularly in those with higher HIV levels or a history of drug use.
- Both direct acting antivirals (DAA) and pegylated-interferon therapies reduced HPgV levels, with sofosbuvir/ledipasvir being the most effective, highlighting possible treatment options for HPgV infections.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!